AU2009315736B2 - Crystalline forms of fingolimod HCL - Google Patents

Crystalline forms of fingolimod HCL Download PDF

Info

Publication number
AU2009315736B2
AU2009315736B2 AU2009315736A AU2009315736A AU2009315736B2 AU 2009315736 B2 AU2009315736 B2 AU 2009315736B2 AU 2009315736 A AU2009315736 A AU 2009315736A AU 2009315736 A AU2009315736 A AU 2009315736A AU 2009315736 B2 AU2009315736 B2 AU 2009315736B2
Authority
AU
Australia
Prior art keywords
weak
fty720
crystalline
salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009315736A
Other languages
English (en)
Other versions
AU2009315736A1 (en
Inventor
Guido Jordine
Michael Mutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2009315736A1 publication Critical patent/AU2009315736A1/en
Priority to AU2013100532A priority Critical patent/AU2013100532B4/en
Priority to AU2013100533A priority patent/AU2013100533B4/en
Priority to AU2013100530A priority patent/AU2013100530B4/en
Priority to AU2013100531A priority patent/AU2013100531B4/en
Application granted granted Critical
Publication of AU2009315736B2 publication Critical patent/AU2009315736B2/en
Priority to AU2013263791A priority patent/AU2013263791B2/en
Priority to AU2016225785A priority patent/AU2016225785A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2009315736A 2008-11-11 2009-11-10 Crystalline forms of fingolimod HCL Ceased AU2009315736B2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2013100532A AU2013100532B4 (en) 2008-11-11 2013-04-12 Crystalline forms of fingolimod HCL
AU2013100533A AU2013100533B4 (en) 2008-11-11 2013-04-12 Crystalline forms of fingolimod HCL
AU2013100530A AU2013100530B4 (en) 2008-11-11 2013-04-12 Crystalline forms of fingolimod HCL
AU2013100531A AU2013100531B4 (en) 2008-11-11 2013-04-12 Crystalline forms of fingolimod HCL
AU2013263791A AU2013263791B2 (en) 2008-11-11 2013-11-28 Crystalline forms of fingolimod HCL
AU2016225785A AU2016225785A1 (en) 2008-11-11 2016-09-05 Crystalline forms of fingolimod HCL

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168865 2008-11-11
EP08168865.7 2008-11-11
PCT/EP2009/064891 WO2010055028A2 (en) 2008-11-11 2009-11-10 Organic compounds

Related Child Applications (5)

Application Number Title Priority Date Filing Date
AU2013100531A Division AU2013100531B4 (en) 2008-11-11 2013-04-12 Crystalline forms of fingolimod HCL
AU2013100533A Division AU2013100533B4 (en) 2008-11-11 2013-04-12 Crystalline forms of fingolimod HCL
AU2013100530A Division AU2013100530B4 (en) 2008-11-11 2013-04-12 Crystalline forms of fingolimod HCL
AU2013100532A Division AU2013100532B4 (en) 2008-11-11 2013-04-12 Crystalline forms of fingolimod HCL
AU2013263791A Division AU2013263791B2 (en) 2008-11-11 2013-11-28 Crystalline forms of fingolimod HCL

Publications (2)

Publication Number Publication Date
AU2009315736A1 AU2009315736A1 (en) 2010-05-20
AU2009315736B2 true AU2009315736B2 (en) 2013-08-29

Family

ID=40521487

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009315736A Ceased AU2009315736B2 (en) 2008-11-11 2009-11-10 Crystalline forms of fingolimod HCL

Country Status (14)

Country Link
US (2) US8530522B2 (enExample)
EP (1) EP2356090B1 (enExample)
JP (4) JP2012508216A (enExample)
KR (2) KR20130109254A (enExample)
CN (3) CN102209705A (enExample)
AU (1) AU2009315736B2 (enExample)
BR (1) BRPI0921826A2 (enExample)
CA (1) CA2743232C (enExample)
ES (1) ES2643161T3 (enExample)
MX (1) MX2011004962A (enExample)
PL (1) PL2356090T3 (enExample)
PT (1) PT2356090T (enExample)
RU (2) RU2549899C2 (enExample)
WO (1) WO2010055028A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041358A1 (en) 2010-10-01 2012-04-05 Synthon B.V. Process for making fingolimod hydrochloride crystals
EP2632889B1 (en) 2010-10-28 2018-08-29 Mapi Pharma Limited Intermediate compounds and process for the preparation of fingolimod
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
WO2012070059A1 (en) * 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
WO2012089238A1 (en) 2010-12-28 2012-07-05 Synthon Bv Process for making fingolimod hydrochloride crystals
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
US9216943B2 (en) 2011-04-29 2015-12-22 Dr. Reddy's Laboratories Ltd. Preparation of fingolimod and its salts
DK2809318T3 (da) 2011-05-26 2019-07-22 Gri Bio Inc Ammoniumholdige sulfonsyre-, phosphonsyre- og carboxylsyrederivater og disses medicinske anvendelse
WO2012160186A1 (en) 2011-05-26 2012-11-29 Jado Technologies Gmbh Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
DK2739606T3 (en) 2011-05-26 2016-07-25 Jado Tech Gmbh Hydroxy-substituted amino and ammonium derivatives and their medical use
US9186333B2 (en) 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
WO2013091704A1 (en) * 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
AU2014206588A1 (en) * 2013-01-17 2015-07-23 Shilpa Medicare Limited Process for preparation of Fingolimod and its salts
US9815772B2 (en) * 2013-03-05 2017-11-14 Biocon Limited Process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
CN106667981B (zh) * 2017-01-16 2019-05-14 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗药物性肝损伤药物中的应用
CN106860440A (zh) * 2017-01-16 2017-06-20 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗系统性红斑狼疮脑病药物中的应用
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
WO2020245775A1 (en) * 2019-06-05 2020-12-10 Biocon Limited Crystalline forms of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol
JP7749552B2 (ja) 2019-10-31 2025-10-06 イドルシア・ファーマシューティカルズ・リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
CN115477590B (zh) 2021-05-31 2023-12-12 上海云晟研新生物科技有限公司 芬戈莫德药用盐、制备方法、含其的药物组合物及应用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69321823T2 (de) 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
JP4079505B2 (ja) * 1998-04-28 2008-04-23 田辺三菱製薬株式会社 ２−アミノ−２−［２−（４−オクチルフェニル）エチル］プロパン−１，３−ジオールの新規な製造法
DK1129066T3 (da) * 1998-11-11 2005-03-29 Novartis Ag Fremstilling af 2-amino-2-[2-(C2-20alkylphenyl)ethyl]propan-1,3-dioler
SI1031347T1 (en) * 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
MXPA01008142A (es) * 1999-02-10 2003-07-21 Welfide Corp Compuestos de amida, y uso medicinal de los mismos.
CN1144779C (zh) * 1999-03-11 2004-04-07 杭州中美华东制药有限公司 制备2-[2-(4-烷基苯基)-乙基]-2-氨基-丙二醇的方法以及其中制得的中间产物
BR0209319A (pt) * 2001-06-08 2004-07-20 Novartis Ag Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina
US20030144712A1 (en) * 2001-12-20 2003-07-31 Jackson Streeter, M.D. Methods for overcoming organ transplant rejection
PT1505959E (pt) * 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
PE20130200A1 (es) * 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
CN1212308C (zh) * 2003-07-24 2005-07-27 漆又毛 2－氨基－2－（2－（4－辛基苯基）乙基）－1，3－丙二醇盐酸盐的制备方法
CN1241903C (zh) * 2003-10-14 2006-02-15 马启明 制备2－对辛基苯乙基－2－氨基丙二醇的方法
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
CA2623826A1 (en) * 2005-09-30 2007-04-12 Novartis Ag Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
CN1310869C (zh) * 2005-11-22 2007-04-18 江苏吴中苏药医药开发有限责任公司 2－氨基－2－[2－(4－烷基苯基)乙基]－1,3－丙二醇的制备方法
CN100548968C (zh) * 2006-03-01 2009-10-14 徐州师范大学 一种制备2-对辛基苯乙基-2-氨基丙二醇盐酸盐的方法
WO2007143081A2 (en) * 2006-06-02 2007-12-13 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
HUE046441T2 (hu) * 2006-09-26 2020-02-28 Novartis Ag S1P modulátort tartalmazó gyógyászati készítmények
JP2011525189A (ja) * 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
WO2012041358A1 (en) 2010-10-01 2012-04-05 Synthon B.V. Process for making fingolimod hydrochloride crystals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIUCHI, M. ET AL., "Synthesis and Immunosuppressive Activity of 2-Substituted 2-Aminopropane-1,3-diols and 2-Aminoethanols", 2000, J. Med. Chem., vol 43, pages 2946-2961. *

Also Published As

Publication number Publication date
JP2014139179A (ja) 2014-07-31
US20140051766A1 (en) 2014-02-20
RU2015111229A (ru) 2015-11-20
CN104788325A (zh) 2015-07-22
EP2356090A2 (en) 2011-08-17
US20110229501A1 (en) 2011-09-22
BRPI0921826A2 (pt) 2016-01-12
US8530522B2 (en) 2013-09-10
MX2011004962A (es) 2011-05-30
RU2549899C2 (ru) 2015-05-10
KR20110069156A (ko) 2011-06-22
CA2743232C (en) 2015-12-29
WO2010055028A2 (en) 2010-05-20
EP2356090B1 (en) 2017-07-05
KR20130109254A (ko) 2013-10-07
RU2015111229A3 (enExample) 2018-11-08
JP2018035160A (ja) 2018-03-08
WO2010055028A3 (en) 2010-07-08
CN102209705A (zh) 2011-10-05
ES2643161T3 (es) 2017-11-21
PL2356090T3 (pl) 2017-12-29
JP2012508216A (ja) 2012-04-05
RU2011123371A (ru) 2012-12-20
JP2016028056A (ja) 2016-02-25
PT2356090T (pt) 2017-10-16
AU2009315736A1 (en) 2010-05-20
KR101393994B1 (ko) 2014-05-14
CN107233336A (zh) 2017-10-10
CA2743232A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
AU2009315736B2 (en) Crystalline forms of fingolimod HCL
AU2009315735B2 (en) Salts of fingolimod
SG181466A1 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
AU2013100533A4 (en) Crystalline forms of fingolimod HCL
AU2013203470A1 (en) Salts of fingolimod

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
GD Licence registered

Name of requester: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired